Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
27 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
- D3.239 - Trimethoprim-induced drug reaction with eosinophilia and systemic symptoms (DRESS) associated with reactivation of human herpesvirus-7 (HHV-7)
- D3.242 - Desensitization to ampicillin fixed drug eruption. Spotting the solution to fix the heart
- D3.243 - Successful subcutaneous desensitization protocols for Canakinumab, Trastuzumab, and Triptorelin: a case series report
- D3.244 - Diagnosing Drug-Induced Sweet Syndrome With Target-Like Lesions Amidst Malignancy And Infection
D3.245 - Positive HLA-B*13:01 Allele in a Patient with Clinical Diagnosis of Drug Induced Eosinophilia with Systemic Symptoms (DRESS)
- D3.246 - Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) induced by enoxaparin: a case report and allergology work up
- D3.247 - A case report of multiple drug hypersensitivity triggered by DRESS to beta-lactamase inhibitors
- D3.248 - Anaphylactic shock after indocyanine green intracervical administration
- D3.249 - Delayed-Type Drug Allergy Combined with Adverse Drug Reactions
- D3.250 - Macrolide Hypersensitivity: Exploring the Value of Skin and Provocation Tests in a Portuguese Case Series
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download